Histology and cytology tests are essential for identifying cancer, inherited, infectious disease and other diseases. This report focuses on tissue and cell diagnostic assays and technologies, providing the world markets for histology and cytology diagnostics for the current market and forecasted to 2018. All of the technologies and applications discussed in this report share the characteristic that they start with tissue or cell specimens. Global revenues are provided, broken out type of technology, including:
- Digital Pathology
- Pap Smear
- HPV Tests
- Flow Cytometry
- Circulating tumor cells (CTCs)
- Hematology (cell assays)
- In situ hybridization (ISH)
- Immunohistochemistry (IHC)
- Stains [non-Pap]
- Traditional Histology
Along with standard technologies are now being applied in this field, including MS mass spectrometry, next-generation sequencing, CTCs, and others. Advanced products in tissue and cell testing are still under development.
A global report, revenues for the overall tissue diagnostics market are broken out by geographical region for 2013 and 2018, covering
- North America
- Europe
- Asia
- Rest of World
In the past, tissue and cell diagnostics work had been highly labor intensive and subjective in results. This is no longer the case. The procedures have been changed in some part by the introduction of automated processes and digital analysis, and the development of cancer gene and HPV molecular tests.
Tissue diagnostics is a rapidly growing market driven by growth in global HPV diagnostics, new precision cancer treatment techniques, and novel companion diagnostic tests for drugs. Flow cytometry platforms have been available for many years. From flow cytometry and slide preparation through analysis, all the way to result reporting, combined and automated solutions enable faster turn-around time while providing standardized results.
The report profiles key companies in the industry, including
- 20/20 GeneSystems, Inc.
- 3DHISTECH Ltd.
- Abbott Laboratories
- Abcam plc
- AB SCIEX (A Danaher Corporation company)
- Adaptive Biotechnologies Corporation
- AdnaGen GmbH (An Alere Company)
- Advanced Cell Diagnostics
- Affymetrix, Inc.
- Agena Bioscience Inc.
- Agendia BV
- Agilent Technologies Inc.
- Aurora Interactive
- AutoGenomics, Inc.
- Aviva BioSciences Corporation
- Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
- Becton Dickinson and Co. (BD)
- Biocare Medical, LLC
- Biocartis S.A.
- Bio-Rad Laboratories, Inc.
- Bruker Corporation
- Cancer Genetics, Inc.
- Canopus Bioscience Ltd.
- Caris Life Sciences
- CellaVision AB
- Dako A/S (An Agilent Technologies Company)
- Danaher Corporation
- DiaTech Oncology
- Elitech Group
- EMD Millipore (Merck Millipore)
- Enzo Biochem, Inc.
- Epic Sciences, Inc.
- Fluidigm Corporation
- GE Healthcare
- Hologic, Inc.
- HORIBA Medical
- Janssen Diagnostics
- Leica Biosystems Inc. (Part of Danaher Corporation)
- Leica Microsystems (A Danaher Company)
- LeucoDx Inc.
- Life Technologies Corporation (Acquired by Thermo Fisher Scientific Inc.)
- MDxHealth SA
- Olympus Group
- Omnyx
- Oxford Gene Technology
- Panagene Inc.
- PerkinElmer, Inc.
- Protea Biosciences Group, Inc.
- Qiagen N.V.
- QuanDx
- QuantuMDx Group
- Rarecells SAS
- Response Genetics, Inc.
- Rheonix, Inc.
- Roche Diagnostics
- Siemens Healthcare Diagnostics
- Ventana Medical Systems Inc. (Member of the Roche Group)
And many other companies...
Market analyses in this report cover world markets for tissue and cell diagnostics. However, the reader will find a bias toward the developed areas of the globe -- North America, Japan and Western Europe, the areas in which most tissue and cell diagnostic testing is currently performed. The information presented is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.